secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bolt Biotherapeutics, Inc. (BOLT)
CIK:        0001641281
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001193125-25-277521
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bolt Biotherapeutics Q3 2025: operating loss $7.7M, cash $38.8M; BDC-4182 data expected 3Q26
--------------------------------------------------------------------------------

- Collaboration revenue $2.2M (vs $1.1M Q3 2024); R&D expenses $6.5M (down 53% YoY).
- Operating loss $7.7M vs $16.4M YoY, reflecting restructuring and discontinuation of BDC-1001.
- Cash and securities $38.8M as of Sep 30, 2025; runway into 2027.
- Initial Phase 1 data for BDC-4182 (claudin 18.2 ISAC) expected 3Q2026.
- Presented preclinical data for next-gen CEA and PD-L1 ISACs at SITC; seeking partner for BDC-3042.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641281/000119312525277521/0001193125-25-277521-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641281/000119312525277521/bolt-20251112.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-277521

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer